Scientific article
OA Policy
English

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study

Published inCirculation, vol. 114, no. 1, p. 48-54
Publication date2006
Abstract

Eisenmenger syndrome is characterized by the development of pulmonary arterial hypertension with consequent intracardiac right-to-left shunt and hypoxemia in patients with preexisting congenital heart disease. Because Eisenmenger syndrome is associated with increased endothelin expression, patients may benefit from endothelin receptor antagonism. Theoretically, interventions that have some effect on the systemic vascular bed could worsen the shunt and increase hypoxemia.

Keywords
  • Adult
  • Antihypertensive Agents/therapeutic use
  • Double-Blind Method
  • Eisenmenger Complex/drug therapy/physiopathology
  • Endothelin Receptor Antagonists
  • Exercise Tolerance/drug effects
  • Female
  • Hemodynamics/drug effects
  • Humans
  • Male
  • Middle Aged
  • Oxygen/analysis
  • Sulfonamides/therapeutic use
  • Treatment Outcome
Citation (ISO format)
GALIÈ, Nazzareno et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. In: Circulation, 2006, vol. 114, n° 1, p. 48–54. doi: 10.1161/CIRCULATIONAHA.106.630715
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
Journal ISSN1524-4539
621views
664downloads

Technical informations

Creation29/01/2015 13:47:00
First validation29/01/2015 13:47:00
Update14/03/2023 23:21:51
Status update14/03/2023 23:21:50
Last indexation31/10/2024 00:26:55
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack